Using A Micro-organism To Make A Protein Or Polypeptide Patents (Class 435/71.1)
-
Patent number: 8153119Abstract: The present invention is directed to engineered enzymatically active bacteriophages that are both capable of killing the bacteria by lysis and dispersing the bacterial biofilm because they have been also engineered to express biofilm-degrading enzymes, particularly dispersin B (DspB), an enzyme that hydrolyzes ?-1,6-N-acetyl-D-glucosamine, a crucial adhesion molecule needed for biofilm formation and integrity in Staphylococcus and E. coli, including E. coli K-12, as well as clinical isolates.Type: GrantFiled: December 18, 2008Date of Patent: April 10, 2012Assignees: Trustees of Boston University, Massachusetts Institute of TechnologyInventors: James J Collins, Timothy Kuan-Ta Lu
-
Patent number: 8153397Abstract: The present invention relates to the construction, expression, and purification of synthetic or recombinant light chain (LC) botulinum neurotoxin genes from all botulinum neurotoxin serotypes. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product is stable and proteolytically active. Methods of using the products of the invention are described.Type: GrantFiled: April 27, 2009Date of Patent: April 10, 2012Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Leonard A. Smith, Melody Jensen
-
Patent number: 8147847Abstract: The present invention relates to protein antigens IcsP2 and SigA2 from Shigella that are common among numerous Shigella types and species and which can protect against shigellosis or other enteric infections when administered as vaccines. In addition, the present invention relates to antigens that are in common between Shigella species and enteroinvasive Escherichia coli (EIEC). The invention also relates to the use of antibodies raised against these antigens and of DNA probes for use in the diagnosis of Shigella and EIEC infections.Type: GrantFiled: October 21, 2009Date of Patent: April 3, 2012Assignee: International Vaccine InstituteInventors: Cecil Czerkinsky, Dong Wook Kim
-
Patent number: 8147844Abstract: Isolated thrombopoietin (TPO), isolated DNA encoding TPO, and recombinant or synthetic methods of preparing and purifying TPO are disclosed. Various forms of TPO are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: December 28, 1994Date of Patent: April 3, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. de Sauvage
-
Patent number: 8148100Abstract: The present invention comprises a method for assaying oxygenase activity the method comprising monitoring oxygenase activity of Mina53.Type: GrantFiled: September 25, 2006Date of Patent: April 3, 2012Assignee: ISIS Innovation LimitedInventors: Christopher Joseph Schofield, Michael Arnold McDonough, Nicolas Joseph Jean Granatino
-
Patent number: 8148111Abstract: A carrier for cell culture is provided which improves the cell proliferativity in serum-free culture and which is free from risk from infection factor contamination. The gist of the features of the present invention is to be formed of a crosslinked poly(meth)acrylic acid (salt) particle (A) and an artificial polypeptide (P) having at least one cell-adhesive minimal amino acid sequence (X) in one molecule and to have a water retention value of from 2 to 50 g/g. The (A) is preferably a particle produced by reversed phase suspension polymerization of an aqueous monomer solution containing (meth)acrylic acid and/or an alkali metal salt of (meth)acrylic acid. The (P) preferably has at least one auxiliary amino acid sequence (Y) in one molecule of the (P). The (X) is preferably an Arg Gly Asp sequence.Type: GrantFiled: March 13, 2007Date of Patent: April 3, 2012Assignee: Sanyo Chemical Industries, Ltd.Inventors: Masato Kurokawa, Kazuhiro Takahashi
-
Patent number: 8143027Abstract: The present invention provides polynucleotides encoding clot-specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes for preparing the proteins.Type: GrantFiled: July 23, 2007Date of Patent: March 27, 2012Assignee: Council of Scientific & Industrial Research of Rafi MargInventors: Girish Sahni, Rajesh Kumar, Chiati Roy, Kammara Rajagopal, Deepak Nihalani, Vasudha Sundaram, Mahavir Yadav
-
Publication number: 20120070435Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.Type: ApplicationFiled: August 15, 2011Publication date: March 22, 2012Applicant: PALADIN LABS, INC.Inventors: Rajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma
-
Patent number: 8138325Abstract: The present invention relates to methods for producing a biological substance, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the biological substance, wherein the fungal host cell comprises a first nucleic acid sequence encoding the biological substance operably linked to a second nucleic acid sequence comprising a promoter variant selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12; and a subsequence thereof; and hybrid and tandem promoters thereof; and (b) isolating the biological substance from the cultivation medium. The present invention also relates to the isolated promoter variants and to constructs, vectors, and fungal host cells comprising the promoter variants operably linked to nucleic acid sequences encoding biological substances.Type: GrantFiled: March 24, 2008Date of Patent: March 20, 2012Assignee: Novozymes, Inc.Inventors: Debbie Yaver, Peter Nham
-
Patent number: 8137929Abstract: The invention is related to a method for purification of recombinant proteins using highly basic proteins from thermophilic bacteria as purification tags for use in a cation-exchange chromatography purification step. The basic proteins may be ribosomal proteins. The recombinant proteins are expressed in eukaryotic or prokaryotic host cells. The purification tag will typically have a pl above about 9 and comprise from about 15 to about 250 amino acid residues.Type: GrantFiled: April 10, 2006Date of Patent: March 20, 2012Assignee: Novo Nordisk Health Care AGInventors: Allan Christian Shaw, Susanne Bang, Jing Su
-
Patent number: 8137940Abstract: The present invention relates to microorganisms genetically engineered to increase yield and/or efficiency of biomass production from a carbon source, such as e.g. glucose. Processes for generating such microorganisms are also provided by the present invention. The invention also relates to polynucleotide sequences comprising genes that encode proteins that are involved in the bioconversion of a carbon source such as e.g. glucose into biomass. The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. Also included are processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms leading to a microorganism with reduced carbon source diversion, i.e. higher yield and/or efficiency of biomass production from a carbon source such as e.g. glucose.Type: GrantFiled: September 7, 2006Date of Patent: March 20, 2012Assignee: DSM IP Assets B.V.Inventor: Masako Shinjoh
-
Patent number: 8138324Abstract: The invention provides a novel system for the tunable expression of nucleic acids encoding e.g., polypeptides such as recombinant proteins in prokaryotic systems. The system is based on the ability of T7 lysozyme (T7Lys) to inhibit the activity of T7RNAP. Expression of T7Lys can be continuously adjusted as its expression is under the control of a promoter whose activity can be titrated. The invention provides a host cell capable of expressing T7 RNA polymerase, the host cell comprising a first nucleic acid having a T7 lysozyme gene or a T7 lysozyme variant gene and a tunable promoter for controlling the expression of the T7 lysozyme gene. It also provides a host cell further comprising a second nucleic acid having a T7 promoter operably linked to a nucleic acid sequence encoding a target polypeptide, whereby expression of the target polypeptide is tuned via controlling the expression of the T7 lysozyme gene.Type: GrantFiled: February 27, 2009Date of Patent: March 20, 2012Assignee: Xbrane Bioscience ABInventors: Jan Willem De Gier, Samuel Wagner
-
Patent number: 8137925Abstract: The invention provides compositions and methods of use thereof for labeling peptide and proteins in vitro or in vivo. The methods described herein employ lipoic acid ligase or mutants thereof, and lipoic acid analogs recognized by lipoic acid ligase and lipoic acid ligase mutants.Type: GrantFiled: November 9, 2007Date of Patent: March 20, 2012Assignee: Massachusetts Institute of TechnologyInventors: Alice Y. Ting, Marta Fernandez Suarez, Hemanta Baruah
-
Patent number: 8137954Abstract: Methods and materials are provided for the production of compositions of erythropoietin protein, wherein said compositions comprise a pre-selected N-linked glycosylation pattern as the predominant N-glycoform.Type: GrantFiled: May 13, 2010Date of Patent: March 20, 2012Assignee: Glycofi, Inc.Inventors: Natarajan Sethuraman, Juergen Nett, Robert Davidson
-
Patent number: 8133711Abstract: The present invention provides BGL7 polypeptides with the biological activity of a ?-glucosidase and a method of producing a recombinant enzyme having ?-glucosidase activity.Type: GrantFiled: June 24, 2008Date of Patent: March 13, 2012Assignee: Danisco US Inc.Inventors: Nigel Dunn-Coleman, Michael Ward
-
Publication number: 20120058514Abstract: The objective of the present invention is to obtain a low temperature producing enzyme and more particularly, the enzyme provides a bifunctional purpose of varying its enzyme activity into activity of another enzyme. The present invention has overcome problems such as ability of obtaining an enzyme at low temperature.Type: ApplicationFiled: September 8, 2010Publication date: March 8, 2012Applicant: UNIVERSITY PUTRA MALAYSIAInventors: RAJA NOOR ZALIHA, ABU BAKAR SALLEH, MAHIRAN BASRI, MOHD SHUKURI BIN MOHAMAD ALI
-
Patent number: 8129139Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.Type: GrantFiled: July 13, 2009Date of Patent: March 6, 2012Assignee: Allergan, Inc.Inventors: Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
-
Patent number: 8129162Abstract: Methods for the evolution of NADPH binding ketol-acid reductoisomerase enzymes to acquire NADH binding functionality are provided. Specific mutant ketol-acid reductoisomerase enzymes isolated from Pseudomonas that have undergone co-factor switching to bind NADH are described.Type: GrantFiled: December 18, 2008Date of Patent: March 6, 2012Assignee: Butamax(TM) Advanced Biofuels LLCInventors: Yougen Li, Der-Ing Liao, Mark J. Nelson, Daniel P. Okeefe
-
Patent number: 8124376Abstract: The present invention relates to methods of producing a heterologous biological substance, comprising: (a) cultivating a mutant of a parent Bacillus cell under conditions conducive for the production of the heterologous biological substance, wherein (i) the mutant cell comprises a first nucleic acid sequence directing synthesis of the heterologous biological substance and a second nucleic acid sequence comprising a modification of at least one of the genes cypX and yvmC, which are involved in the production of a red pigment, and (ii) the mutant cell is deficient in the production of the red pigment compared to the parent Bacillus cell when cultivated under the same conditions; and (b) recovering the heterologous biological substance from the cultivation medium. The present invention also relates to mutants of Bacillus cells and methods for producing the mutants.Type: GrantFiled: February 10, 2010Date of Patent: February 28, 2012Assignee: Novozymes, Inc.Inventors: Maria Tang, Alan Sloma, Leslie Naggiar, legal representative, David Sternberg, Linda Sternberg, legal representative, Regine Behr
-
Patent number: 8124377Abstract: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.Type: GrantFiled: October 18, 2010Date of Patent: February 28, 2012Assignee: Taiwan Advance Bio-Pharm Inc.Inventors: Kou-Juey Wu, Chi-Hung Huang
-
Patent number: 8119383Abstract: A thermostable glycosidase enzymes derived from various Thermococcus, Staphylothermus and Pyrococcus organisms is disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the food processing industry, pharmaceutical industry and in the textile industry, detergent industry and in the baking industry.Type: GrantFiled: August 20, 2010Date of Patent: February 21, 2012Assignee: BP Corporation North America Inc.Inventors: Edward J. Bylina, Ronald Swanson, Eric Mathur, David E. Lam
-
Patent number: 8119369Abstract: The inventive subject matter relates to novel compositions, methods, and kits for enhancing the expression, solubility, and isolation of heterologous proteins. Further, the inventive subject matter relates to methods for generating proteins with novel N-terminal amino acids, unlike wild-type proteins which always are translated from mRNA with methionine at the N-terminus.Type: GrantFiled: December 30, 2005Date of Patent: February 21, 2012Assignee: Lifesensors, Inc.Inventors: Xun Zuo, David E. Sterner, Tauseef R. Butt
-
Patent number: 8119146Abstract: HBsAg is expressed in a Saccharomyces cerevisiae host, carrying a plasmid having a HBsAg coding sequence, wherein the plasmid includes: (1) an upstream promoter from a glyceraldehyde-3-phosphate dehydrogenase gene, for controlling expression of the HBsAg coding sequence; and (2) an ARG3 transcription terminator downstream of the HBsAg coding sequence. The plasmids may also include: (3) a LEU2 selection marker; (4) a 2? plasmid sequence; and (5) an origin of replication functional in Escherichia coli. HBsAg can be expressed in this host, and can be purified for use in the manufacture of vaccines, and in particular for the manufacture of combination vaccines and in new monovalent HBV vaccines e.g. with non-alum adjuvants.Type: GrantFiled: April 14, 2006Date of Patent: February 21, 2012Inventor: Angelica Medina-Selby
-
Patent number: 8119185Abstract: The invention relates to a security material comprising a carrier and at least one photochromic Protein and/or a mutein of a photochromic protein. The security material is characterized in that it comprises at least one irreversible photosensitive layer on the carrier, and the at least one photochromic protein and/or mutein is contained at least in the at least one photosensitive layer and/or in an optional additional layer. The inventive security material is also characterized in that it is highly forgery-proof, the photochromic biomolecule cannot be removed therefrom in a usable form, and the photochromic biomolecule does not need to be supplied to a large group of clients.Type: GrantFiled: March 28, 2006Date of Patent: February 21, 2012Assignees: Philips-Universitaet Marburg, InovisCoat GmbHInventors: Norbert Hampp, Martin Neebe, Arno Schmuck, Peter Roggendorf
-
Patent number: 8114651Abstract: A highly active L-isoleucine dioxygenase from Bacillus thuringiensis is provided. A method for manufacturing (2S,3R,4S)-4-hydroxy-L-isoleucine or a salt thereof by reacting L-isoleucine in an aqueous solvent in the presence of L-isoleucine dioxygenase and isolating (2S,3R,4S)-4-hydroxy-L-isoleucine is also provided.Type: GrantFiled: March 27, 2009Date of Patent: February 14, 2012Assignee: Ajinomoto Co., Inc.Inventors: Tomohiro Kodera, Sergey Vasilievich Smirnov, Natalia Nikolaevna Samsonova, Veronika Aleksandrovna Kotliarova, Natalia Yurievna Rushkevich, Yury Ivanovich Kozlov, Vitaly Grigorievich Paraskevov, legal representative, Sakayu Shimizu, Jun Ogawa, Makoto Hibi
-
Patent number: 8114632Abstract: The present invention relates to a method of producing a biologically active polypeptide having insulinotropic activity, the method comprising steps of: (a) transforming a genetically modified host cell that has protease gene knockout, with a polynucleotide vector encoding the polypeptide; and (b) growing the transformed host cell to produce the biologically active polypeptide; and a method of producing a biologically active polypeptide having an N-terminal recognition site His-Gly with insulinotropic activity, the method comprising steps of: (a) transforming a genetically modified Pichia pastoris that has protease gene STE13 knockout, with a polynucleotide vector encoding the polypeptide; and (b) growing the transformed Pichia pastoris to produce the biologically active polypeptide.Type: GrantFiled: June 20, 2007Date of Patent: February 14, 2012Assignee: Biocon LimitedInventors: Ramakrishnan Melarkode, Akundi Venkata Sriram, Kedarnath Nanjund Sastry, Lakshmi Prabha Varadarajalu, Shrikumar Suryanarayan
-
Patent number: 8114635Abstract: The present invention relates to microbial trypsin variants having chymotrypsin-like activity, comprising: (a) a one or more substitutions corresponding to positions 144, 193, 198, 201, 218, 223, 227, 228, 229, 230, and 231 of amino acids 25 to 248 of SEQ ID NO: 2, (b) one or more deletions corresponding to positions 192, 197, and 226 of amino acids 25 to 248 of SEQ ID NO: 2; and (c) an insertion between positions corresponding to positions 224 and 225 of amino acids 25 to 248 of SEQ ID NO: 2. The present invention further relates to nucleotide sequences encoding microbial trypsin variants having chymotrypsin-like activity; nucleic acid constructs, expression vectors, and recombinant host cells comprising such nucleotide sequences; and methods of producing microbial trypsin variants having chymotrypsin-like activity or a precursor thereof.Type: GrantFiled: February 18, 2010Date of Patent: February 14, 2012Assignee: Novozymes, Inc.Inventors: Alan Klotz, Kimberly M. Brown, Elizabeth J. Zaretsky
-
Patent number: 8114626Abstract: The present invention embraces a fungal strain deficient in nicotinamide riboside import and salvage and use thereof for producing nicotinamide riboside. Methods for producing nicotinamide riboside and a nicotinamide riboside-supplemented food product using the strain of the invention are also provided.Type: GrantFiled: March 26, 2009Date of Patent: February 14, 2012Assignee: Trustees of Dartmouth CollegeInventors: Charles Brenner, Peter Belenky, Katrina L. Bogan
-
Patent number: 8114655Abstract: The present invention provides a novel endoglucanase nucleic acid sequence, designated egl7, and the corresponding EGVII amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding EGVII, recombinant EGVII proteins and methods for producing the same.Type: GrantFiled: October 13, 2008Date of Patent: February 14, 2012Assignee: Danisco US Inc.Inventors: Nigel Dunn-Coleman, Frits Goedegebuur, Michael Ward, Jian Yao
-
Patent number: 8110388Abstract: The present invention provides novel lysophosphatidic acid acyltransferase genes. A nucleic acid comprising the nucleotide sequence shown in SEQ ID NO: 1, 3, 36 or 37 or a fragment thereof.Type: GrantFiled: May 23, 2008Date of Patent: February 7, 2012Assignee: Suntory Holdings LimitedInventors: Misa Ochiai, Hisanori Tokuda
-
Patent number: 8105799Abstract: Revealed are that the actions of inflammatory cytokine and the production of inflammatory cytokines such as IL-1 and TNF induced by an inflammatory stimulus as well as the production of other inflammatory cytokines such as IL-6 induced by the former class of inflammatory cytokines are all suppressed by inhibiting the signal transduction through TAK1.Type: GrantFiled: February 6, 2008Date of Patent: January 31, 2012Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masayuki Tsuchiya, Toshihiko Ohtomo, Yasuhiro Sugamata, Kunihiro Matsumoto
-
Patent number: 8097443Abstract: The present invention provides mutant RmlA enzymes possessing an increased purine/pyrimidine bias in nucleotide triphosphate substrate specificity as compared to a corresponding non-mutated RmlA enzyme. Such enzymes expand the types of substrates that can be used in enzymatic glycorandomization methods thereby increasing diversity of chemical libraries.Type: GrantFiled: April 16, 2008Date of Patent: January 17, 2012Assignee: Wisconsin Alumni Research FoundationInventor: Jon S. Thorson
-
Publication number: 20120011619Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: September 21, 2011Publication date: January 12, 2012Applicant: NOVOZYMES, INC.Inventors: Alfredo Lopez de Leon, Hanshu Ding, Kimberly Brown
-
Patent number: 8093019Abstract: A fermentation process using hemicellulose-derived carbohydrates for the production of cellulase mixtures with a high proportion of cellulases relative to hemicellulases is provided. The cellulases produced by the process of the invention are further characterized by high specific productivity. The resulting cellulase mixtures comprise at least two times more cellulase than hemicellulase and are useful for the hydrolysis of cellulosic substrated, particularly, pretreated lignocellulosic substrate.Type: GrantFiled: August 28, 2008Date of Patent: January 10, 2012Assignee: Iogen Energy CorporationInventors: Jason B. Edwards, Brian E. Foody, Glenn D. Munkvold
-
Patent number: 8093045Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Type: GrantFiled: September 13, 2007Date of Patent: January 10, 2012Assignee: Abbott LaboratoriesInventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, David Chang Yu-Hsiang, Thomas Seewoester
-
Publication number: 20120003692Abstract: A method of producing an ?-L-aspartyl-L-phenylalanine-?-ester by forming the ?-L-aspartyl-L-phenylalanine-?-ester from L-aspartic acid-?,?-diester and L-phenylalanine using an enzyme or enzyme-containing substance that has an ability to selectively link L-phenylalanine to an ?-ester site of the L-aspartic acid-?,?-diester through a peptide bond.Type: ApplicationFiled: August 4, 2011Publication date: January 5, 2012Applicant: Ajinomoto Co., Inc.Inventors: Kenzo YOKOZEKI, Ayako Ohno, Seiichi Hara, Isao Abe
-
Patent number: 8088613Abstract: The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition methods of designing new nitrilases and method of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.Type: GrantFiled: May 4, 2010Date of Patent: January 3, 2012Assignee: Verenium CorporationInventors: Mark Burk, Kelly Chatman, Grace Desantis, Bob Farwell, Jay M. Short, Kelvin Wong
-
Publication number: 20110318387Abstract: The object of the present invention is to provide an immunization method which allows efficient preparation of a desired antibody. The present invention provides a method for immunizing a laboratory animal, which comprises the following steps: (1) transplanting cancer cells having a metastatic potential and capable of expressing an antigen into the laboratory animal; and (2) allowing the cancer cells to be engrafted in the laboratory animal to thereby immunize the laboratory animal.Type: ApplicationFiled: February 26, 2010Publication date: December 29, 2011Inventors: Hiroyuki Satofuka, Masahiro Uchino, Hiroko Kojima
-
Patent number: 8084239Abstract: Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 mn/280 nm and 1.359 at 260 nm/230 nm.Type: GrantFiled: April 27, 2009Date of Patent: December 27, 2011Assignee: Ohr Pharmaceuticals, IncInventors: Shalom Z. Hirschman, Irach B. Taraporewala
-
Patent number: 8084235Abstract: The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatography material in the presence of detergent and high salt.Type: GrantFiled: March 11, 2004Date of Patent: December 27, 2011Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Biemans, Karine Goraj, Emmanuel Mertens, Annick Vandercammen
-
Patent number: 8080395Abstract: An isolated mutant of coryneform bacteria comprising a gene encodes a polypeptide having 2-methylcitrate dehydratase activity, where the polypeptide comprises an amino acid sequence in which one of the proteinogenic amino acids except L-proline is present at position 272 or a corresponding or comparable position. In addition, an isolated polynucleotide encoding a polypeptide having 2-methylcitrate dehydratase enzymic activity, which comprises at position 272 of the amino acid sequence or a corresponding or comparable position a proteinogenic amino acid except L-proline is described. A method for producing a recombinant coryneform bacterium and L-amino acids. A recombinant microorganism, L-Lysine-containing feed additive, and L-Tryptophan-containing feed additive is also described.Type: GrantFiled: January 19, 2011Date of Patent: December 20, 2011Assignee: Evonik Degussa GmbHInventors: Brigitte Bathe, Caroline Kreutzer, Georg Thierbach
-
Patent number: 8076109Abstract: The present invention relates to processes for producing a fermentation product, such as ethanol, from milled starch-containing material comprising (a) saccharifying the milled starch-containing material with a glucoamylase having an amino acid sequence shown in SEQ ID NO: 2, or a glucoamylase being at least 70% identical thereto, at a temperature below the initial gelatinization temperature of said starch-containing material, (b) fermenting using a fermenting organism.Type: GrantFiled: April 4, 2011Date of Patent: December 13, 2011Assignees: Novozymes A/S, Novozymes North America, Inc.Inventors: Eric Allain, Kevin S. Wenger, Henrik Bisgard-Frantzen
-
Patent number: 8076114Abstract: Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3.Type: GrantFiled: April 5, 2010Date of Patent: December 13, 2011Assignee: California Institute of TechnologyInventors: Edgardo T Farinas, Frances H. Arnold, Ulrich Schwaneberg, Anton Glieder
-
Patent number: 8071748Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for transporting sugars across cell membranes using isolated and/or purified polypeptides and nucleic acid sequences from Alicyclobacillus acidocaldarius.Type: GrantFiled: April 19, 2011Date of Patent: December 6, 2011Assignee: Battelle Energy Alliance, LLCInventors: David N. Thompson, William A. Apel, Vicki S. Thompson, David W. Reed, Jeffrey A. Lacey
-
Patent number: 8071351Abstract: The present invention relates to xyloglucanases belonging to family 44 of glycosyl hydrolases and having a relative xyloglucanase activity of at least 30% between pH 5 and pH 8 are derived from the genus Paenibacillus, especially from a strain of Paenibacillus polymyxa or Paenibacillus sp. The xyloglucanases exhibit high performance in conventional detergent compositions.Type: GrantFiled: May 13, 2010Date of Patent: December 6, 2011Assignee: Novozymes A/SInventors: Kirk Schnorr, Martin Schulein, Hanne Dela, legal representative, Per Lina Jorgensen
-
Patent number: 8071736Abstract: Compositions and methods for protecting a plant from an insect pest are provided. In particular, nucleic acid sequences encoding insect protoxins modified to comprise at least one proteolytic activation site that is sensitive to a plant protease or an insect gut protease are provided. Cleavage of the modified protoxin at the proteolytic activation site by a protease produces an active insect toxin. Methods of using the modified insect protoxin nucleic acid sequences and the polypeptides they encode to protect a plant from an insect pest are provided. Particular embodiments of the invention further provide modified insect protoxin compositions and formulations, expression cassettes, and transformed plants, plant cells, and seeds.Type: GrantFiled: July 30, 2009Date of Patent: December 6, 2011Assignees: Pioneer Hi-Bred International, Inc., E.I. Dupont de Nemours and CompanyInventors: Andre R. Abad, Ronald D. Flannagan, Rafael Herrmann, Albert L. Lu, Billy F. McCutchen, James K. Presnail, Janet A. Rice, James F. Wong, Cao-Guo Yu
-
Patent number: 8071745Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.Type: GrantFiled: April 25, 2007Date of Patent: December 6, 2011Assignees: Novartis AG, Universite de StrasbourgInventors: Thierry Léveillard, José Alain Sahel, Saddek Mohand-Said, David Hicks
-
Patent number: 8071347Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.Type: GrantFiled: September 14, 2010Date of Patent: December 6, 2011Assignee: Codexis, Inc.Inventors: Charlene Ching, John M. Gruber, Gjalt W. Huisman, Emily Mundorff, Lisa M. Newman
-
Publication number: 20110296558Abstract: The present invention relates to isolated polypeptides having expansin activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: January 29, 2010Publication date: December 1, 2011Applicant: Novozymes, IncInventors: Alfredo Lopez de Leon, Michael Rey, Paul Harris
-
Patent number: 8067221Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: GrantFiled: April 16, 2008Date of Patent: November 29, 2011Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki